IM Cannabis (IMCC) Projected to Post Earnings on Monday

IM Cannabis (NASDAQ:IMCC) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect IM Cannabis to post earnings of $0.0860 per share and revenue of $15.6620 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 9:00 AM ET.

IM Cannabis Stock Performance

NASDAQ IMCC opened at $0.62 on Monday. The stock has a market capitalization of $3.65 million, a price-to-earnings ratio of -0.79 and a beta of 2.17. The business’s 50 day moving average is $1.05 and its two-hundred day moving average is $1.45. IM Cannabis has a 12-month low of $0.54 and a 12-month high of $7.12. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 0.25.

Institutional Trading of IM Cannabis

A hedge fund recently bought a new stake in IM Cannabis stock. DRW Securities LLC purchased a new stake in IM Cannabis Corp. (NASDAQ:IMCC) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,060 shares of the company’s stock, valued at approximately $32,000. DRW Securities LLC owned about 0.39% of IM Cannabis at the end of the most recent reporting period. Institutional investors and hedge funds own 7.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IM Cannabis in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

IM Cannabis Company Profile

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.